



Investor Presentation

March 2024

A circular inset image on the left side of the slide shows a male doctor in a white lab coat and stethoscope examining a female patient. The doctor is using a stethoscope on the patient's chest. The patient is smiling and looking at the doctor. The background of the inset shows a medical office setting with a poster of a human figure on the wall.

WE ARE BIOCON BIOLOGICS

Biosimilars aren't just what we do

*They're **ALL** we do*

Biocon Biologics is a Subsidiary of Biocon Limited



Biocon Business Segments



62%

Expanding access through innovative, inclusive healthcare solutions

REVENUE CONTRIBUTION¹: 62%



17%

Ensuring access through quality, affordability, reliability

REVENUE CONTRIBUTION¹: 17%



21%

Partnering to deliver innovative scientific solutions

REVENUE CONTRIBUTION¹: 21%

Biocon Limited is a Bengaluru based biopharma company listed on the Indian Stock Exchange



¹Q3'FY24

Biocon Biologics At A Glance



Unique, fully
integrated leading
global biosimilars player



Global reach in
100+
countries



Top 15
in global
biomanufacturing
capacity



25+
cGMP approvals
received from key
regulatory agencies



Diverse talent
pool of
5,500+
people



1,500+
patents granted



Portfolio of
20
biosimilars



8
Commercial Products in
Global Markets



>5.5M
Patients served



Vision

To be a **global leader**
in biologics delivering
affordable access to
innovative and inclusive
healthcare solutions,
transforming patients' lives

Core Values



Value Creation Through Innovation & Differentiation



Quality Through Compliance & Best Practices



Collaboration, Teamwork & Mutual Respect




Integrity & Ethical Behavior




Performance Driven Work Culture

45-year Legacy of being on the Cutting Edge of Science



Successfully transformed from an enzymes company to a leading global biopharma enterprise

Setting New Benchmarks for the Biosimilars Industry



Achieved many global 'firsts' in the biosimilars space

US\$3B+ Acquisition of Viatris' Global Biosimilars Business



A unique, fully integrated
biosimilar player



One of the **largest** deal in the industry



Business **acquired** across **120** countries



Successfully integrated in just **1** year




End-to-end capabilities from **lab** to market

A Unique, Fully Integrated Global Biosimilars Player



Research & Development



Manufacturing




Commercialization



Proven capabilities across the value chain

Transforming Healthcare. Transforming Lives.

Cutting-Edge Science & Technology Capabilities



Inspired by Patients. Driven by Science



Commitment to innovation and value creation



Proven track record of scientific success



Innovative and proprietary technology platforms



Robust track record of generating IP



Experience working with key regulators

3

R&D sites

1,500+

Patents granted

20

Portfolio Products

9

Approved Products

Note: Patent numbers reflect overall Biocon Group patents

Transforming Healthcare. Transforming Lives.

One of the Highest Manufacturing Capacities in the Industry



	Company	Total Capacity (KL)
1	Roche Genentech	982
2	SANOFI	879
3	gsk GlaxoSmithKline	727
4	SAMSUNG BIOLOGICS	623
5	Pfizer	610
6	AMGEN	602
7	Lilly	571
8	novo nordisk	555
9	FUJIFILM Value from Innovation	546
10	Lonza	465

	Company	Total Capacity (KL)
11	Boehringer Ingelheim	441
12	NOVARTIS SANDOZ A Novartis Division	436
13	CELLTRION	389
14	Biocon Biologics	368
15	MERCK	328
16	Bristol Myers Squibb™ (includes Celgene & Juno)	323
17	AstraZeneca MedImmune	281
18	Biogen	275
19	Johnson & Johnson	272
20	REGENERON	255

Committed to
supply reliability
and quality
compliance









Source: 19th Annual Report and Summary of Biopharmaceutical Manufacturing Capacity and Production, BioPlan Associates 2022



We reach patients in
100+ countries



Portfolio: 20 Biosimilars across Therapy Areas

	Commercial / Approved	Late Stage	Early Stage
 Oncology	<ul style="list-style-type: none"> ✓ Pegfilgrastim ✓ Trastuzumab ✓ Bevacizumab 	<ul style="list-style-type: none"> ✓ Denosumab ✓ Pertuzumab 	<ul style="list-style-type: none"> ✓ 2 undisclosed
 Immunology	<ul style="list-style-type: none"> ✓ Adalimumab ✓ Etanercept 	<ul style="list-style-type: none"> ✓ Ustekinumab 	<ul style="list-style-type: none"> ✓ 3 undisclosed
 Diabetes	<ul style="list-style-type: none"> ✓ Glargine U100 ✓ rh-Insulin ✓ Aspart 		<ul style="list-style-type: none"> ✓ Glargine U300 ✓ 1 undisclosed
 Bone Health		<ul style="list-style-type: none"> ✓ Denosumab 	
 Ophthalmology	<ul style="list-style-type: none"> ✓ Aflibercept 		
 Others			<ul style="list-style-type: none"> ✓ 1 undisclosed




**Robust pipeline with
several new launches on
the horizon**

Portfolio unlocks a US\$100B+ Global Opportunity



Significant opportunity to make a meaningful difference to patient lives



Full year CY'22 IQVIA sales for Originator & biosimilars used as base data. Launch assumed 1 Qtr. post approval | LOE not factored

One of the most Comprehensive Portfolios in the Industry



	Trastuzumab	✓			✓	✓	✓	✓	✓
	Bevacizumab	✓		✓	✓	✓	✓	✓	✓
	Pegfilgrastim	✓	✓	✓				✓	✓
	Filgrastim							✓	✓
	Rituximab			✓		✓	✓	✓	✓
	Adalimumab	✓	✓	✓	✓	✓	✓	✓	✓
	Etanercept	✓		✓	✓	✓			✓
	Infliximab				✓	✓	✓	✓	✓
	Ustekinumab	✓	✓	✓	✓	✓	✓		✓
	Ranibizumab				✓				✓
	Aflibercept	✓	✓		✓	✓	✓		✓
	Denosumab	✓	✓	✓	✓	✓			✓
	Insulin Glargine	✓							✓
	Insulin Aspart	✓							✓
	Insulin Lispro								✓

Sources: Public disclosures, BBL research; *Fresenius includes mAbxience portfolio

ESG: Going Beyond Financials to Have a Positive Impact

Committed to Managing Performance and Improving Outcomes



**Driving
'Patient Equity'**
Improve access to
high quality
biotherapeutics



**Creating
'People Equity'**
Build an empowering
and inclusive
workplace



**Promoting
'Environment Equity'**
Adapting
sustainable
business practices



**Ensuring
'Stakeholder Equity'**
Operate with integrity,
transparency and
accountability



**Enabling
'Social Equity'**
For underserved
communities



Our ESG Strategy Pillars

ESG Efforts Being Recognized Globally

Recognized among
World's Most Sustainable Companies in **S&P Global 2023**
Sustainability Yearbook



Improved **ESG score to 63** in the 2022
Sustainability Assessment from
52



CDP scores at '**B**'
for **Water Security** & '**C**' for
Climate Change



Won **UNWEP India Award** and
Transparency & Reporting Asia-Pacific Winner




Joins **UNGC**, the
world's largest
Corporate Sustainability



Strong Financial Performance backed by Marquee Investors



Well poised
to create
significant
value for
shareholders



Investments

	\$700M+	Fixed Assets
	\$400M+	R&D Investments
	\$500M+	Private Equity Investments
















Experienced Global Leadership Team



**KIRAN
MAZUMDAR SHAW**

Executive Chairperson,
Biocon & Biocon Biologics



SHREEHAS P TAMBE

Chief Executive Officer &
Managing Director



KEDAR UPADHYE

Chief Financial Officer



MATTHEW ERICK

Chief Commercial Officer –
Advanced Markets



SUSHEEL UMESH

Chief Commercial Officer –
Emerging Markets



SANDEEP N. ATHALYE

Chief Development Officer



RHONDA DUFFY

Chief Operating Officer



NAVEEN NARAYANAN

Global Head of HR



PAUL THOMAS

Global Head –
Portfolio and Program Management



GANESH REDDY

Global Head of Manufacturing



KIRAN KUMAR GANDHIRAJAN

Global Head, Procurement & External
Manufacturing



Dwight D. Hanshew, Jr

Chief Quality Officer



ANUJ GOEL

Global Head of R&D - CMC



SEEMA AHUJA

Global Head - Corporate Brand & Head of
Communications – Emerging Markets



STEPHANIE WASCO

Head of Communications –
Advanced Markets



STEPHEN FECHO

Global Head of SCM



AKHILESH NAND

General Counsel – Emerging Markets



STEPHEN MANZANO

General Counsel – Advanced Markets



MANDAR GHATNEKAR

Global Head of IT and
Digital Transformation



Arlene Wolny

Global Head of Regulatory Affairs



Uwe Gudat

Chief Medical Officer



Thank You!

